Researchers in the Cancer Immunology, Inflammation and Tolerance program use a range of techniques to study how the immune system influences tumorigenesis and cancer therapy. The immune system can inhibit or promote tumor progression in local tissues where pre-malignancies form. Major program themes are to elucidate
The scientific rationale for this dual approach is that pre-malignant cells create and sustain tolerance during tumor progression, while breaking tumor-associated tolerance is necessary for successful anti-tumor treatment. Hence, program goals are to elucidate molecular and cellular pathways at sites of inflammation that promote or break immune tolerance using pre-clinical mouse models of tumor progression and autoimmune syndromes, and developing novel immunotherapies to treat these syndromes more effectively by targeting tolerance pathways. To this end, program faculty also engage in promoting pre-clinical research and early-phase clinical trials of novel vaccine adjuvants to improve cancer immunotherapy, in some cases with corporate partners.
To pursue these focused research themes and scientific goals, program faculty employ many state-of-the-art techniques, facilities, and unique resources, including flow cytometric sorting and analysis, a range of molecular imaging techniques, genomic analysis, and genetically modified mouse strains. Future program development will build on existing CIT program strengths by recruiting new investigators with expertise in inflammation, immunological, and metabolic research to complement current research focused on regulation of adaptive immunity.
Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.
Learn how a researcher at the Georgia Cancer Center is working to eliminate Georgia's breast cancer disparities.
Georgia Cancer Center researcher tackles clinical trial hesitancy in the Black community in the southeast.
MCG and Georgia Cancer Center scientists have early evidence that the peptide EnnA, isolated from a fungus living symbiotically with a flowering plant known for its penchant of trapping flies, could be a powerful opponent of aggressive triple negative breast cancer.
